Overview
A previous venous thromboembolism — a deep vein thrombosis or a pulmonary embolism — is one of the most significant considerations in a hormone therapy decision, and it is one of the few where specialist input is genuinely required rather than advisable.
The core fact that shapes everything: oral estrogen increases clot risk. Transdermal estradiol, in the available evidence, does not.
| Oral estrogen | Transdermal estradiol | |
|---|---|---|
| First pass through the liver | Yes | No |
| Effect on clotting factors | Increases production | Does not appear to |
| Venous clot risk vs no treatment | Increased | Not increased in observational evidence |
| With a previous clot | Generally avoided | Possible in some cases, with specialist input |
| Evidence quality | Consistent observational data; mechanism understood | Same — observational, not randomized head-to-head |
Where this leaves you: a previous clot is a strong reason to avoid oral estrogen. Whether transdermal is appropriate depends on why the clot happened, whether a clotting disorder is present, whether you are on anticoagulation, and how severe your symptoms are. That is a conversation involving the clinician who manages your clotting history, not one to settle here.
Why the route makes the difference
The mechanism is well understood and it explains the whole comparison.
Oral estrogen is absorbed into the portal vein and passes through the liver before reaching general circulation — arriving there at a much higher concentration than any other tissue sees. The liver responds by changing what it produces, including increased production of clotting factors and changes to the body's natural anticoagulant proteins. The net effect shifts toward clotting.
Transdermal estradiol is absorbed through skin into the general circulation, so the liver encounters it at ordinary concentrations alongside everything else. Those hepatic changes largely do not occur.
Observational studies have consistently found increased venous clot risk with oral estrogen and no detectable increase with transdermal estradiol at standard doses. The fact that the mechanism explains the finding strengthens the case considerably beyond association alone.
The honest limitation: this evidence is observational rather than randomized. A head-to-head trial powered for clot outcomes in women with a previous clot has not been done and realistically will not be. So the position rests on consistent observational data plus a well-understood mechanism — which is good, and which is not the same as proof.
What determines the answer for you
Not one thing. Several, and they interact.
Why the clot happened. A clot provoked by a clear temporary cause — major surgery, a long period of immobility, a plaster cast — carries a different ongoing risk from an unprovoked clot with no identifiable trigger. Unprovoked clots suggest a persistent underlying tendency.
Whether a thrombophilia is present. Inherited clotting disorders — Factor V Leiden, prothrombin gene variants, antithrombin, protein C or protein S deficiency, and antiphospholipid syndrome — change the assessment substantially. Antiphospholipid syndrome in particular is generally regarded as a contraindication to systemic estrogen.
Whether you are on anticoagulation, and whether that is short-term or indefinite.
How long ago it was, and whether there have been recurrences.
Your family history, which may point to an undiagnosed inherited tendency.
How severe your symptoms are. The benefit side of the equation is real, and severe vasomotor symptoms that are wrecking sleep and daily function weigh differently from mild ones.
Who needs to be involved
This is the part that matters most practically.
The clinician who manages your clotting history — a hematologist, or whoever oversaw the clot and any anticoagulation. Their input is not a formality; they hold information about your specific risk that a menopause consultation does not.
Whoever would prescribe the hormone therapy, working with rather than around that assessment.
And you, with an honest account of how much the symptoms are affecting you — because this is a genuine trade-off and your weighting of it is part of the decision.
What should not happen is a hormone therapy prescription issued without that history being surfaced and assessed. If you have had a clot and nobody has asked about it, that is the gap to close.
What is available if systemic estrogen is not appropriate
Being unable to take systemic hormone therapy does not mean nothing can be done, and the alternatives here are real.
Local vaginal estrogen for dryness, discomfort with sex and urinary symptoms. Systemic absorption at standard low doses is minimal, so the clot considerations do not apply in the same way. This is the most under-used effective treatment in menopause care and it remains available to most women in this situation. What it does.
Non-hormonal prescription options for vasomotor symptoms, several with genuine evidence behind them.
Cognitive behavioral therapy, which has good evidence for reducing how much vasomotor symptoms interfere with daily life.
The modifiable contributors — alcohol, smoking, a cooler bedroom, weight — which matter more when hormonal treatment is off the table. What helps with night sweats.
When to seek urgent attention
Worth stating on any page about clots, for anyone with a history of one.
A swollen, painful, warm calf or thigh. Sudden breathlessness, chest pain worse on breathing in, or coughing blood. Sudden severe headache, weakness, numbness, speech difficulty or visual loss.
Those need emergency assessment, not an appointment.
Also worth knowing: periods of immobility raise risk temporarily — long flights, surgery, illness — and are worth planning around if you are on any systemic treatment.
Frequently asked questions
Can I take HRT after a blood clot? Oral estrogen is generally avoided. Transdermal may be possible in some circumstances, depending on why the clot happened, whether a clotting disorder is present and what your symptoms are — assessed with the clinician managing your clotting history.
Why is transdermal different? Oral estrogen passes through the liver at high concentration and increases clotting factor production. Transdermal is absorbed into the general circulation and does not produce those hepatic changes.
Does that mean transdermal is definitely safe for me? No. The evidence is observational and it concerns populations. Your own risk depends on your clot history, any clotting disorder and your other factors — which is what the assessment is for.
What if I have Factor V Leiden or another thrombophilia? It changes the assessment substantially and requires specialist input. Antiphospholipid syndrome in particular is generally regarded as a contraindication to systemic estrogen.
What can I use instead? Local vaginal estrogen for genitourinary symptoms, non-hormonal prescription options for vasomotor symptoms, and cognitive behavioral therapy all remain available.
Where this fits in your plan
This is one of the situations where the right answer genuinely cannot be reached from an article, and where the assessment involves more than one clinician.
What is worth taking from here: the route matters enormously, the reason for the original clot matters, and the alternatives are real rather than a consolation. What hormone therapy with us involves.
We measure first. Then we act.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
